Insider Selling: Natera (NASDAQ:NTRA) CEO Sells $866,983.68 in Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 3,648 shares of Natera stock in a transaction dated Wednesday, January 28th. The shares were sold at an average price of $237.66, for a total value of $866,983.68. Following the completion of the transaction, the chief executive officer owned 213,180 shares of the company’s stock, valued at approximately $50,664,358.80. This represents a 1.68% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Steven Leonard Chapman also recently made the following trade(s):

• On Tuesday, January 27th, Steven Leonard Chapman sold 2,322 shares of Natera stock. The stock was sold at an average price of $240.53, for a total value of $558,510.66.
• On Wednesday, January 21st, Steven Leonard Chapman sold 1,590 shares of Natera stock. The shares were sold at an average price of $235.00, for a total value of $373,650.00.
• On Tuesday, January 20th, Steven Leonard Chapman sold 71,932 shares of Natera stock. The stock was sold at an average price of $234.74, for a total value of $16,885,317.68.
• On Friday, January 2nd, Steven Leonard Chapman sold 3,848 shares of Natera stock. The shares were sold at an average price of $229.08, for a total value of $881,499.84.
• On Monday, December 1st, Steven Leonard Chapman sold 4,400 shares of Natera stock. The shares were sold at an average price of $238.07, for a total transaction of $1,047,508.00.
• On Monday, November 3rd, Steven Leonard Chapman sold 160,703 shares of Natera stock. The stock was sold at an average price of $199.96, for a total transaction of $32,134,171.88.

Natera Stock Down 0.1%

NTRA opened at $231.14 on Friday. The firm’s fifty day simple moving average is $235.91 and its two-hundred day simple moving average is $194.11. Natera, Inc. has a 52-week low of $125.38 and a 52-week high of $256.36. The company has a market cap of $31.97 billion, a price-to-earnings ratio of -100.93 and a beta of 1.62.

Natera (NASDAQ:NTRA) last released its earnings results on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). The company had revenue of $592.18 million for the quarter, compared to analysts’ expectations of $514.55 million. Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The firm’s revenue for the quarter was up 34.7% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.26) EPS. On average, research analysts forecast that Natera, Inc. will post -1.49 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Sigma Planning Corp acquired a new position in shares of Natera in the 4th quarter valued at $700,000. Citizens Financial Group Inc. RI purchased a new stake in Natera in the 4th quarter valued at about $271,000. Precision Wealth Strategies LLC lifted its position in Natera by 29.5% in the fourth quarter. Precision Wealth Strategies LLC now owns 5,794 shares of the medical research company’s stock valued at $1,327,000 after buying an additional 1,319 shares during the last quarter. Trifecta Capital Advisors LLC purchased a new position in Natera during the fourth quarter worth about $115,000. Finally, Moody Aldrich Partners LLC acquired a new stake in shares of Natera during the fourth quarter valued at about $269,000. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

NTRA has been the subject of several recent research reports. TD Cowen reissued a “buy” rating on shares of Natera in a research note on Wednesday, January 7th. Morgan Stanley raised their price target on shares of Natera from $220.00 to $265.00 and gave the stock an “overweight” rating in a research note on Monday, December 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a research note on Thursday, January 22nd. UBS Group raised their target price on shares of Natera from $218.00 to $280.00 and gave the stock a “buy” rating in a research note on Tuesday, November 18th. Finally, BTIG Research upped their price target on Natera from $230.00 to $260.00 and gave the company a “buy” rating in a research report on Friday, December 5th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Natera presently has a consensus rating of “Moderate Buy” and a consensus price target of $249.20.

Natera News Summary

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera announced completion of enrollment in the randomized ACES‑EMB heart‑transplant trial — a clinical milestone for the transplant franchise (Prospera) that de‑risks the program’s pathway to clinical readouts and potential uptake. Article Title
• Positive Sentiment: Wall Street coverage remains largely favorable: multiple firms maintain buy/outperform views and several have raised targets (MarketBeat summary shows consensus around a “Moderate Buy” and an average target near $249). This supports upside expectations if results and growth continue.
• Neutral Sentiment: Natera reported preliminary Q4 revenue (details in the alert). Preliminary figures may influence sentiment when the final quarter report and guidance are released; investors should watch the formal Q4 release for confirmation versus consensus. Preliminary Q4 Revenue
• Neutral Sentiment: Institutional ownership remains extremely high (~99.9%), which tends to stabilize the shareholder base but can also concentrate selling/Buying flows when large holders move. (Source: MarketBeat summary.) Institutional Data
• Negative Sentiment: Multiple insider sales by senior executives: CFO Michael Burkes Brophy sold several tranches (totaling 5,064 shares across Jan. 20–29) and CEO Steven Chapman sold several thousand shares (roughly 5,970 shares across Jan. 27–28). These trades total millions of dollars and may create short‑term selling pressure despite insiders retaining large residual stakes. CFO Form 4 CEO Form 4
• Negative Sentiment: Other insiders (John Fesko, Solomon Moshkevich) also sold smaller tranches. While each reduction is under ~1% of those insiders’ holdings, the cluster of sales amplifies negative signaling to the market. Fesko Form 4 Moshkevich Form 4

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.